eFFECTOR Therapeutics (EFTR) Set to Announce Earnings on Friday

eFFECTOR Therapeutics (NASDAQ:EFTR) is set to post its quarterly earnings results on Friday, March 8th.

eFFECTOR Therapeutics Stock Down 10.1 %

Shares of NASDAQ:EFTR traded down $1.69 during midday trading on Thursday, hitting $14.99. 158,895 shares of the stock traded hands, compared to its average volume of 135,981. The business’s 50 day moving average is $11.80 and its two-hundred day moving average is $13.37. The stock has a market capitalization of $38.67 million, a PE ratio of -0.79 and a beta of 0.52. eFFECTOR Therapeutics has a one year low of $8.44 and a one year high of $37.00.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright upped their target price on eFFECTOR Therapeutics to $24.00 and gave the stock a “buy” rating in a report on Tuesday, February 6th.

Institutional Trading of eFFECTOR Therapeutics

Several institutional investors have recently made changes to their positions in EFTR. State Street Corp purchased a new position in shares of eFFECTOR Therapeutics during the first quarter valued at about $68,000. Renaissance Technologies LLC purchased a new position in eFFECTOR Therapeutics during the 2nd quarter valued at approximately $42,000. Two Sigma Investments LP purchased a new position in eFFECTOR Therapeutics during the 3rd quarter valued at approximately $27,000. CI Private Wealth LLC bought a new stake in eFFECTOR Therapeutics in the 4th quarter worth approximately $118,000. Finally, Sea Otter Advisors LLC purchased a new stake in shares of eFFECTOR Therapeutics during the 1st quarter worth approximately $93,000. Hedge funds and other institutional investors own 57.67% of the company’s stock.

eFFECTOR Therapeutics Company Profile

eFFECTOR Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer.